AR087091A1 - Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso - Google Patents

Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso

Info

Publication number
AR087091A1
AR087091A1 ARP120102464A ARP120102464A AR087091A1 AR 087091 A1 AR087091 A1 AR 087091A1 AR P120102464 A ARP120102464 A AR P120102464A AR P120102464 A ARP120102464 A AR P120102464A AR 087091 A1 AR087091 A1 AR 087091A1
Authority
AR
Argentina
Prior art keywords
factor viii
subject
chain
administering
level
Prior art date
Application number
ARP120102464A
Other languages
English (en)
Original Assignee
Biogen Idec Hemophilia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Hemophilia Inc filed Critical Biogen Idec Hemophilia Inc
Publication of AR087091A1 publication Critical patent/AR087091A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Un método de administrar Factor VIII a un sujeto que lo necesita, que comprende administrar al sujeto una dosis terapéutica de un polipéptido quimérico que comprende una porción del Factor VIII y una segunda porción en un intervalo de dosis al menos aproximadamente una y medio veces más largo que el intervalo de dosis requerido para una dosis equivalente de un polipéptido que consiste en dicha porción del Factor VIII, donde dicha porción del Factor VIII comprende el Factor VIII procesado, que tiene dos cadenas, una primera cadena que comprende una cadena pesada y una segunda cadena que comprende una cadena liviana, donde dicha primera cadena y dicha segunda cadena se asocian con un enlace metálico. Reivindicación 39: Una composición que comprende un polipéptido quimérico que tiene actividad de Factor VIII, donde al menos aproximadamente 30%, aproximadamente 40%, aproximadamente 50%, aproximadamente 60%, aproximadamente 70%, aproximadamente 80%, aproximadamente 90%, aproximadamente 95%, aproximadamente 96%, aproximadamente 97%, aproximadamente 98%, aproximadamente 99%, o aproximadamente 100% de dicho polipéptido comprende a porción del Factor VIII, que es el Factor VIII de cadena simple, y una segunda porción, donde dicho Factor VIII de cadena simple es al menos 90% ó 95% idéntica a una secuencia de aminoácidos del Factor VIII que se muestra en la Tabla 2 sin una secuencia señal (aminoácidos 20 a 1457 de la SEQ ID Nº 2 o aminoácidos 20 a 2351 de la SEQ ID Nº 6). Reivindicación 73: Un método de tratar una afección de sangrado que comprende administrar una cantidad terapéuticamente efectiva de la composición de acuerdo con cualquiera de las reivindicaciones 39 - 72. Reivindicación 81: Un método de mantener el Factor VIII en una población de pacientes a un nivel superior a 1% durante al menos un día, dos días, o tres días que comprende administrar una cantidad terapéuticamente efectiva de rFVIIIFc a dicha población, donde la cantidad terapéuticamente efectiva es al menos 25 IU/kg de rFVIIIFc y donde al menos 90% de dicha población mantiene el nivel mínimo del Factor VIII al menos 1% o más. Reivindicación 105: Un método de prevenir, disminuir, o tratar un episodio de sangrado en un sujeto que comprende: (a) identifican un sujeto que tiene niveles altos de VWF por la medición del nivel de VWF en el plasma de dicho sujeto, donde un nivel de VWF de al menos aproximadamente 100 IU/dL identifica el sujeto que tiene un alto nivel de VWF; y (b) administrar al sujeto una cantidad efectiva de una proteína de FVIII de acción prolongada.
ARP120102464A 2011-07-08 2012-07-06 Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso AR087091A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161506015P 2011-07-08 2011-07-08
US201161522647P 2011-08-11 2011-08-11
US201161541561P 2011-09-30 2011-09-30
US201161569158P 2011-12-09 2011-12-09
US201261586443P 2012-01-13 2012-01-13
US201261622789P 2012-04-11 2012-04-11
US201261657641P 2012-06-08 2012-06-08

Publications (1)

Publication Number Publication Date
AR087091A1 true AR087091A1 (es) 2014-02-12

Family

ID=47506823

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102464A AR087091A1 (es) 2011-07-08 2012-07-06 Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso

Country Status (27)

Country Link
US (3) US10010622B2 (es)
EP (3) EP4169525A1 (es)
JP (5) JP2014522838A (es)
KR (2) KR101829603B1 (es)
CN (2) CN103796670A (es)
AR (1) AR087091A1 (es)
AU (3) AU2012282875B2 (es)
BR (1) BR112014000466A2 (es)
CA (1) CA2841066C (es)
CL (1) CL2014000024A1 (es)
CO (1) CO6940381A2 (es)
CY (1) CY1122900T1 (es)
DK (2) DK3513804T3 (es)
EA (1) EA029045B1 (es)
ES (2) ES2913994T3 (es)
HR (2) HRP20220639T1 (es)
HU (1) HUE043763T2 (es)
IL (2) IL230333B (es)
LT (2) LT3513804T (es)
MX (1) MX350581B (es)
MY (1) MY180714A (es)
PL (2) PL2729161T3 (es)
PT (2) PT2729161T (es)
RS (2) RS58578B1 (es)
SI (2) SI2729161T1 (es)
TW (3) TWI626947B (es)
WO (1) WO2013009627A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2558102T3 (es) * 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
ES2521490T3 (es) 2006-12-15 2014-11-12 Baxter International Inc. Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada.
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011017055A2 (en) 2009-07-27 2011-02-10 Baxter International Inc. Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2590679T3 (es) 2009-07-27 2016-11-23 Lipoxen Technologies Limited Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
BR112012013502A2 (pt) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
MX345608B (es) 2010-12-22 2017-02-07 Baxalta Inc Materiales y metodos para conjugar un derivado de acido graso soluble en agua a una proteina.
EA029045B1 (ru) * 2011-07-08 2018-02-28 Байоджен Хемофилия Инк. Химерные и гибридные полипептиды фактора viii и способы их применения
US10317376B2 (en) 2012-04-11 2019-06-11 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
WO2014070953A1 (en) * 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
DK3889173T3 (da) 2013-02-15 2023-10-09 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
EA201890671A1 (ru) * 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. Препараты полипептида фактора viii
US9234757B2 (en) 2013-11-29 2016-01-12 Fedex Corporate Services, Inc. Determining node location using a variable power characteristic of a node in a wireless node network
US10453023B2 (en) 2014-05-28 2019-10-22 Fedex Corporate Services, Inc. Methods and node apparatus for adaptive node communication within a wireless node network
US11238397B2 (en) 2015-02-09 2022-02-01 Fedex Corporate Services, Inc. Methods, apparatus, and systems for generating a corrective pickup notification for a shipped item using a mobile master node
US10305744B2 (en) 2015-07-08 2019-05-28 Fedex Corporate Services, Inc. System, apparatus, and methods of event monitoring for an event candidate related to an ID node within a wireless node network
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
CN108780538A (zh) 2016-03-23 2018-11-09 联邦快递服务公司 用于自调整无线节点网络中的节点的广播设定的系统、设备和方法
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
AU2018366110A1 (en) 2017-11-07 2020-06-04 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
EP3765064A1 (en) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
US20210024603A1 (en) 2018-03-16 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
EP3765065A2 (en) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
US20210024631A1 (en) * 2018-03-28 2021-01-28 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
SG11202010767SA (en) * 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
EP3962516A4 (en) * 2019-05-03 2023-01-04 Rani Therapeutics, LLC COAGULATION FACTOR PREPARATIONS TO BE DELIVERED INTO INTESTINAL TRACT TISSUE BY MEANS OF A SWALLOWED DRUG DELIVERY DEVICE
KR20220024628A (ko) 2019-06-19 2022-03-03 바이오버라티브 테라퓨틱스 인크. 혈우병 및 낮은 골 무기질 밀도를 치료하기 위한 재조합 인자 viii-fc
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
DK0461200T3 (da) 1989-02-21 1997-03-10 Univ Washington Modificerede former af reproduktionshormoner
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
EP1572889B1 (en) * 2001-10-05 2008-12-17 Expression Therapeutics, LLC Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
ES2558102T3 (es) 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
LT3130601T (lt) 2004-11-12 2020-09-10 Bayer Healthcare Llc Į vietą nukreipta fviii modifikacija
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
SG123635A1 (en) 2004-12-28 2006-07-26 Nanoscience Innovation Pte Ltd Nanostructured zinc oxide and a method of producing the same
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
JP5448839B2 (ja) * 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
DK2393828T3 (en) 2009-02-03 2017-01-23 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
BR112012013502A2 (pt) * 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
EP3508573A1 (en) * 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
DK2591099T3 (da) * 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
EA029045B1 (ru) * 2011-07-08 2018-02-28 Байоджен Хемофилия Инк. Химерные и гибридные полипептиды фактора viii и способы их применения

Also Published As

Publication number Publication date
CN107261122A (zh) 2017-10-20
EA201490039A1 (ru) 2014-06-30
HUE043763T2 (hu) 2019-09-30
JP7273487B2 (ja) 2023-05-15
IL230333B (en) 2020-05-31
DK3513804T3 (da) 2022-06-20
CL2014000024A1 (es) 2014-11-21
SI3513804T1 (sl) 2022-07-29
PT3513804T (pt) 2022-06-02
TWI687226B (zh) 2020-03-11
JP2023134851A (ja) 2023-09-27
BR112014000466A2 (pt) 2017-02-21
ES2913994T3 (es) 2022-06-07
EP2729161A4 (en) 2015-06-24
ES2722209T3 (es) 2019-08-08
US10881742B2 (en) 2021-01-05
EP3513804B1 (en) 2022-03-23
AU2018202936B2 (en) 2020-07-02
TW202042838A (zh) 2020-12-01
MX350581B (es) 2017-09-11
LT2729161T (lt) 2019-04-10
US20140294821A1 (en) 2014-10-02
CA2841066C (en) 2023-09-26
MY180714A (en) 2020-12-07
NZ619438A (en) 2016-06-24
HRP20220639T1 (hr) 2022-07-08
CY1122900T1 (el) 2021-05-05
LT3513804T (lt) 2022-05-25
RS63241B1 (sr) 2022-06-30
EP3513804A1 (en) 2019-07-24
TW201822788A (zh) 2018-07-01
DK2729161T3 (en) 2019-04-08
WO2013009627A3 (en) 2013-03-07
WO2013009627A2 (en) 2013-01-17
AU2016204986A1 (en) 2016-08-04
JP2014522838A (ja) 2014-09-08
TW201315480A (zh) 2013-04-16
RS58578B1 (sr) 2019-05-31
US10010622B2 (en) 2018-07-03
JP2022003096A (ja) 2022-01-11
AU2016204986B2 (en) 2018-05-10
KR102110736B1 (ko) 2020-05-14
PL3513804T3 (pl) 2022-07-11
AU2012282875A1 (en) 2013-05-02
TWI764092B (zh) 2022-05-11
EP2729161B1 (en) 2018-12-19
JP2019048877A (ja) 2019-03-28
TWI626947B (zh) 2018-06-21
EP2729161A2 (en) 2014-05-14
CN103796670A (zh) 2014-05-14
MX2014000202A (es) 2014-10-06
AU2012282875B2 (en) 2016-04-21
HRP20190535T1 (hr) 2019-05-17
US20180360982A1 (en) 2018-12-20
PT2729161T (pt) 2019-04-01
KR20180020305A (ko) 2018-02-27
CO6940381A2 (es) 2014-05-09
EP4169525A1 (en) 2023-04-26
IL271870A (en) 2020-02-27
AU2018202936A1 (en) 2018-05-17
KR101829603B1 (ko) 2018-02-19
JP2017088623A (ja) 2017-05-25
CA2841066A1 (en) 2013-01-17
US20210220476A1 (en) 2021-07-22
EA029045B1 (ru) 2018-02-28
PL2729161T3 (pl) 2019-08-30
IL271870B (en) 2022-04-01
SI2729161T1 (sl) 2019-05-31
KR20140066157A (ko) 2014-05-30

Similar Documents

Publication Publication Date Title
AR087091A1 (es) Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso
CY1123385T1 (el) Υψηλης συγγενειας pd-1 παραγοντες και μεθοδοι χρησης
CY1122800T1 (el) Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
CO2018005215A2 (es) Construcciones específicas del hígado para expresión del factor viii
PE20191345A1 (es) Administracion viral de neoantigenos
AR093626A1 (es) Proteinas de fusion de enzima lisosomal y usos de las mismas
AR086998A1 (es) Coagonistas del receptor de glucagon/glp-1
AR068302A1 (es) Peptidos para vacunas para canceres que expresan antigenos asociados con tumores
ECSP15014133A (es) Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida
AR085281A1 (es) Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso
AR087567A1 (es) Anticuerpos anti-tie2 y usos de los mismos
IN2014KN01713A (es)
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
IN2014KN01714A (es)
AR105822A1 (es) Análogos de insulina
EA201200515A1 (ru) Полипептиды и их применение
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
GT201700224A (es) Proteína de unión a rgma y su uso
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
CY1118856T1 (el) Εμβολιο pcsk9
PE20191786A1 (es) Anticuerpo monoclonal para pd-l1

Legal Events

Date Code Title Description
FC Refusal